Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
stomach cancer
Biotech
I-Mab buys Bridge Health for $3M to strengthen givastomig push
I-Mab has solidified its pivot to givastomig by buying out the owner of an antibody used in the therapy.
James Waldron
Jul 17, 2025 8:45am
Amgen, Zai say stomach cancer candidate hits phase 3 mark
Jun 30, 2025 10:36am
CARsgen touts phase 2 stomach cancer win for cell therapy
Jan 2, 2025 10:42am
Roche, EarlySign add AI-powered lung cancer diagnosis to collab
Jul 8, 2022 10:24am
Biopharma charts progress in translating CAR-T to solid cancers
Dec 15, 2021 3:00am
Insights into esophageal cancer could boost early detection
Aug 12, 2021 2:00pm
